RegentAtlantic Capital’s Elevance Health ELV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $20.1M | Sell |
44,315
-726
| -2% | -$347K | 0.6% | 24 |
|
|
2022
Q2 | $21.7M | Sell |
45,041
-1,875
| -4% | -$928K | 0.72% | 21 |
|
|
2022
Q1 | $23M | Sell |
46,916
-1,118
| -2% | -$511K | 0.65% | 26 |
|
|
2021
Q4 | $22.3M | Sell |
48,034
-735
| -2% | -$309K | 0.62% | 25 |
|
|
2021
Q3 | $18.2M | Sell |
48,769
-1,450
| -3% | -$551K | 0.55% | 30 |
|
|
2021
Q2 | $19.2M | Sell |
50,219
-577
| -1% | -$221K | 0.59% | 28 |
|
|
2021
Q1 | $18.2M | Sell |
50,796
-1,698
| -3% | -$546K | 0.62% | 24 |
|
|
2020
Q4 | $16.9M | Sell |
52,494
-3,508
| -6% | -$1.08M | 0.67% | 26 |
|
|
2020
Q3 | $15M | Sell |
56,002
-2,161
| -4% | -$581K | 0.68% | 26 |
|
|
2020
Q2 | $15.3M | Sell |
58,163
-866
| -1% | -$231K | 0.85% | 20 |
|
|
2020
Q1 | $13.4M | Sell |
59,029
-603
| -1% | -$164K | 1.04% | 21 |
|
|
2019
Q4 | $18M | Sell |
59,632
-900
| -1% | -$248K | 1.09% | 18 |
|
|
2019
Q3 | $14.5M | Sell |
60,532
-1,279
| -2% | -$350K | 0.96% | 20 |
|
|
2019
Q2 | $17.4M | Sell |
61,811
-25
| -0% | -$6.83K | 1.18% | 16 |
|
|
2019
Q1 | $17.7M | Sell |
61,836
-8,497
| -12% | -$2.46M | 1.24% | 13 |
|
|
2018
Q4 | $18.5M | Sell |
70,333
-1,718
| -2% | -$472K | 1.57% | 12 |
|
|
2018
Q3 | $19.7M | Sell |
72,051
-1,470
| -2% | -$382K | 1.51% | 10 |
|
|
2018
Q2 | $17.5M | Buy |
73,521
+372
| +0.5% | +$86.1K | 1.51% | 8 |
|
|
2018
Q1 | $16.1M | Buy |
73,149
+1,416
| +2% | +$333K | 1.34% | 9 |
|
|
2017
Q4 | $16.1M | Sell |
71,733
-613
| -0.8% | -$131K | 1.32% | 9 |
|
|
2017
Q3 | $13.7M | Buy |
72,346
+524
| +0.7% | +$99.7K | 1.19% | 15 |
|
|
2017
Q2 | $13.5M | Sell |
71,822
-118
| -0.2% | -$21.2K | 1.23% | 13 |
|
|
2017
Q1 | $11.9M | Sell |
71,940
-1,905
| -3% | -$303K | 1.1% | 20 |
|
|
2016
Q4 | $10.6M | Sell |
73,845
-75
| -0.1% | -$10K | 1.04% | 24 |
|
|
2016
Q3 | $9.26M | Buy |
73,920
+471
| +0.6% | +$60.8K | 0.96% | 26 |
|
|
2016
Q2 | $9.65M | Sell |
73,449
-3,031
| -4% | -$415K | 0.93% | 25 |
|
|
2016
Q1 | $10.6M | Sell |
76,480
-5,699
| -7% | -$762K | 1.17% | 16 |
|
|
2015
Q4 | $11.5M | Sell |
82,179
-796
| -1% | -$110K | 1.22% | 17 |
|
|
2015
Q3 | $11.6M | Buy |
82,975
+518
| +0.6% | +$77.8K | 1.12% | 19 |
|
|
2015
Q2 | $13.5M | Buy |
82,457
+183
| +0.2% | +$29.2K | 1.21% | 16 |
|
|
2015
Q1 | $12.7M | Buy |
82,274
+5,116
| +7% | +$728K | 1.11% | 19 |
|
|
2014
Q4 | $9.7M | Buy |
77,158
+5,356
| +7% | +$662K | 0.82% | 30 |
|
|
2014
Q3 | $8.59M | Buy |
71,802
+927
| +1% | +$106K | 0.8% | 31 |
|
|
2014
Q2 | $7.63M | Sell |
70,875
-9
| -0% | -$927 | 0.71% | 36 |
|
|
2014
Q1 | $7.06M | Buy |
70,884
+633
| +0.9% | +$57.3K | 0.69% | 38 |
|
|
2013
Q4 | $6.49M | Buy |
70,251
+1,652
| +2% | +$147K | 0.63% | 40 |
|
|
2013
Q3 | $5.74M | Buy |
68,599
+4,311
| +7% | +$369K | 0.63% | 41 |
|
|
2013
Q2 | $5.26M | Buy |
+64,288
| New | +$4.81M | 0.62% | 41 |
|
Other funds holding ELV
RegentAtlantic Capital's ELV Position: Q3 2022 in Review
RegentAtlantic Capital reduced its Elevance Health (ELV) stake by 1.6% in Q3 2022, selling an estimated $347K and leaving 44,315 shares worth $20.1M. The position accounts for 0.6% of the portfolio, ranked #24.
RegentAtlantic Capital first reported a position in ELV in Q2 2013 and has held it in 38 quarters since. The position peaked at $23M in Q1 2022. 1,445 funds tracked by Wall St. Rank hold ELV as of Q3 2022.
- RegentAtlantic Capital held 44,315 shares of Elevance Health worth $20.1M as of Q3 2022.
- RegentAtlantic Capital sold 726 Elevance Health shares in Q3 2022, an estimated $347K.
- Elevance Health made up 0.6% of RegentAtlantic Capital's portfolio in Q3 2022, its #24 holding.
- RegentAtlantic Capital first reported a position in Elevance Health in Q2 2013 and has held it in 38 quarters since.
- RegentAtlantic Capital's Elevance Health position peaked at $23M in Q1 2022.
- 1,445 funds tracked by Wall St. Rank held Elevance Health as of Q3 2022.
Based on RegentAtlantic Capital's 13F filing for Q3 2022, filed 14 Nov 2022.